Xiang-Yu Wang, Bo Zhang, Yin-Chen Gu, Mei Yang, Bao-Rui Tao, Rong-Quan Sun, Yi-Tong Li, Zhen-Mei Chen, Sen-Feng Ying, Chen-He Yi, Yan Geng, Rui Zhang, Jie Fan, Jin-Hong Chen
{"title":"The prognostic significance of histopathological growth patterns in liver metastases undergoing surgery: a systematic review and meta-analysis.","authors":"Xiang-Yu Wang, Bo Zhang, Yin-Chen Gu, Mei Yang, Bao-Rui Tao, Rong-Quan Sun, Yi-Tong Li, Zhen-Mei Chen, Sen-Feng Ying, Chen-He Yi, Yan Geng, Rui Zhang, Jie Fan, Jin-Hong Chen","doi":"10.1007/s10585-025-10361-2","DOIUrl":null,"url":null,"abstract":"<p><p>Histopathological growth pattern (HGP) is emerging as a promising pathological biomarker in liver metastases, with potential associations to prognosis and response to antiangiogenic therapy. Nonetheless, its prognostic role requires further elucidation for substantial heterogeneity of previous studies. We searched PubMed, Web of Science, Embase and Cochrane Library for studies comparing the overall survival (OS) or disease-free survival (DFS) between different HGPs in liver metastases from various cancer types. Data were pooled using hazard ratios (HRs) along with 95% confidence intervals (CIs) according to fixed or random-effects models. Subgroup analysis was also performed to adjust critical confounders. In total, 36 studies were included in the final analysis. It was demonstrated that desmoplastic HGP (dHGP) was associated with favorable OS compared with non-dHGP (HR, 0.59; 95% CI 0.54-0.64), replacement HGP (rHGP, HR, 0.60; 95% CI 0.49-0.74) and pushing HGP (pHGP, HR, 0.63; 95% CI 0.43-0.92), respectively. Similarly, dHGP also demonstrated improved DFS compared with non-dHGP (HR, 0.58; 95% CI 0.52-0.65), rHGP (HR, 0.61; 95% CI 0.49-0.77) and pHGP (HR, 0.51; 95% CI 0.31-0.83), respectively. In subgroup analysis, dHGPs remains an independent prognostic factor regardless of critical confounders, such as the preoperative systemic therapy, cancer types and HGP categorization criteria. This study confirmed the prognostic role of HGPs in liver metastases receiving surgical resection. Clinically, adding HGPs in prognostic models may provide further optimization.</p>","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":"42 5","pages":"41"},"PeriodicalIF":4.2000,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Experimental Metastasis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10585-025-10361-2","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Histopathological growth pattern (HGP) is emerging as a promising pathological biomarker in liver metastases, with potential associations to prognosis and response to antiangiogenic therapy. Nonetheless, its prognostic role requires further elucidation for substantial heterogeneity of previous studies. We searched PubMed, Web of Science, Embase and Cochrane Library for studies comparing the overall survival (OS) or disease-free survival (DFS) between different HGPs in liver metastases from various cancer types. Data were pooled using hazard ratios (HRs) along with 95% confidence intervals (CIs) according to fixed or random-effects models. Subgroup analysis was also performed to adjust critical confounders. In total, 36 studies were included in the final analysis. It was demonstrated that desmoplastic HGP (dHGP) was associated with favorable OS compared with non-dHGP (HR, 0.59; 95% CI 0.54-0.64), replacement HGP (rHGP, HR, 0.60; 95% CI 0.49-0.74) and pushing HGP (pHGP, HR, 0.63; 95% CI 0.43-0.92), respectively. Similarly, dHGP also demonstrated improved DFS compared with non-dHGP (HR, 0.58; 95% CI 0.52-0.65), rHGP (HR, 0.61; 95% CI 0.49-0.77) and pHGP (HR, 0.51; 95% CI 0.31-0.83), respectively. In subgroup analysis, dHGPs remains an independent prognostic factor regardless of critical confounders, such as the preoperative systemic therapy, cancer types and HGP categorization criteria. This study confirmed the prognostic role of HGPs in liver metastases receiving surgical resection. Clinically, adding HGPs in prognostic models may provide further optimization.
组织病理学生长模式(HGP)正在成为肝转移的一种有前景的病理生物标志物,与预后和抗血管生成治疗的反应有潜在的关联。尽管如此,其预后作用还需要进一步阐明,因为之前的研究存在很大的异质性。我们检索了PubMed、Web of Science、Embase和Cochrane Library,以比较不同类型癌症肝转移患者不同HGPs之间的总生存期(OS)或无病生存期(DFS)。根据固定或随机效应模型,采用风险比(hr)和95%置信区间(ci)对数据进行汇总。还进行了亚组分析以调整关键混杂因素。总共有36项研究被纳入最终分析。结果表明,与非dHGP相比,结缔组织增生HGP (dHGP)与良好的OS相关(HR, 0.59;95% CI 0.54-0.64),替代HGP (rHGP, HR, 0.60;95% CI 0.49-0.74)和推高HGP (pHGP, HR, 0.63;95% CI 0.43-0.92)。同样,与非dHGP相比,dHGP也表现出改善的DFS (HR, 0.58;95% CI 0.52-0.65), rHGP (HR, 0.61;95% CI 0.49-0.77)和pHGP (HR 0.51;95% CI 0.31-0.83)。在亚组分析中,无论术前系统治疗、癌症类型和HGP分类标准等关键混杂因素如何,dHGPs仍然是一个独立的预后因素。本研究证实了hgp在肝转移灶手术切除中的预后作用。临床上,在预后模型中加入hgp可能会提供进一步的优化。
期刊介绍:
The Journal''s scope encompasses all aspects of metastasis research, whether laboratory-based, experimental or clinical and therapeutic. It covers such areas as molecular biology, pharmacology, tumor biology, and clinical cancer treatment (with all its subdivisions of surgery, chemotherapy and radio-therapy as well as pathology and epidemiology) insofar as these disciplines are concerned with the Journal''s core subject of metastasis formation, prevention and treatment.